Idera Pharmaceuticals Announces Organizational Update
April 18, 2017 16:01 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., April 18, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
Idera Pharmaceuticals Advances Investigational Treatment – Intratumoral IMO-2125 in Combination with Ipilimumab - for Unmet Need in Anti-PD-1 Refractory Metastatic Melanoma
April 11, 2017 07:00 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual Meeting
April 05, 2017 07:00 ET
|
Idera Pharmaceuticals, Inc.
WASHINGTON, April 05, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients...
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update
March 15, 2017 16:30 ET
|
Idera Pharmaceuticals, Inc.
- IMO-2125 Confirmed Responses in PD-1 Refractory Melanoma Appear Durable - - First Third Generation Antisense (3GA) Target Selected; Poised to Enter Clinical Development in 2018 - CAMBRIDGE, Mass....
Idera to Present at the 37th Annual Cowen and Company Health Care Conference
March 02, 2017 07:30 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., March 02, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium
February 24, 2017 11:30 ET
|
Idera Pharmaceuticals, Inc.
ORLANDO, Fla., Feb. 24, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients...
Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development
February 06, 2017 08:00 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
Idera to Present at the 35th Annual J.P. Morgan Healthcare Conference
January 04, 2017 12:00 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement for the Worldwide Rights to IMO-9200
November 28, 2016 07:00 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass., EXTON, Pa. and HAMILTON, Bermuda, Nov. 28, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), and Vivelix Pharmaceuticals, Ltd. today announced that they have...
Idera Pharmaceuticals Reports Translational Data Supporting the Mechanism of Action of Intratumoral IMO-2125 from Ongoing Phase 1 Dose Escalation in Clinical Trial in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment
November 11, 2016 15:15 ET
|
Idera Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and EXTON, Pa., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...